cagrisema cagrilintide semaglutide phase 3 results 2024 2025 Novo Nordisk has officially filed for FDA approval of CagriSema, a powerful new once-weekly injection that combines a GLP-1 receptor agonist with an amylin analogue, setting the stage for the next major CagriSema Outperforms Semaglutide Alone Across

Triple agonist retatrutide delivered weight loss and osteoarthritis pain relief in TRIUMPH-4

Its possible to do this with lifestyle changes alone like diet, exercise, managing stress and sleep but its rare

Choosing Morning, Afternoon, or Evening for Your Weekly Injection Many patients prefer injecting on the same morning each week, often on a Monday, because it creates an easy-to-remember routine and integrates seamlessly into their weekly schedule

doi: 10.1186/s13054-025-05516-2 58

Kim SM, Kwon EJ, Oh JY, Kim HS, Park S, Jang G, et al

We introduced GMP peptides to give our customers more options, especially for those needing them for clinical or regulated use